People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...
Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within o ...
GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small study. Here's what doctors have to say.
Hosted on MSN19h
Allurion’s weight loss balloon back on French marketAllurion’s CEO confirmed to Medical Device Network that the company has changed advertising, patient follow-up, and physician ...
The use of glucagon-like peptide-1 receptor agonists is likely to increase the risks of inadequate bowel preparation for colonoscopy, according to a study published Feb. 12 in The American Journal of ...
Commercials run by Hims & Hers advertise prescription injectable weight-loss drugs without disclosing safety and risk information.
The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback